EXOMNIS BIOTECH

Their core work

Exomnis Biotech is a Maastricht-based biotech SME focused on cancer immunotherapy, particularly developing targeted biological delivery systems for immunomodulatory drugs. Their core work involves using engineered Clostridium bacteria as precision delivery vehicles for cancer therapeutics, and they contribute expertise to clinical trials combining immunotherapy with stereotactic ablative radiotherapy (SABR). They operate at the intersection of microbiology, oncology, and drug delivery — a niche but commercially relevant space in precision cancer treatment.

What they specialise in

How they've shifted over time

Exomnis Biotech's H2020 involvement spans a narrow window (2015–2017 start dates), making long-term evolution difficult to assess. Their early work centered on radiation therapy education and training (RADIATE, 2015), while their 2017 projects show a clear pivot toward clinical immunotherapy applications — combining SABR with immunomodulators (IMMUNOSABR) and developing bacterial delivery systems (CMI2T IA). The trajectory suggests a move from supporting radiation research toward developing proprietary immunotherapy delivery technology.

Exomnis appears to be building toward proprietary biological drug delivery platforms for cancer immunotherapy, making them a potential partner for clinical-stage immuno-oncology projects.

How they like to work

Exomnis Biotech primarily joins projects as a third party or partner (3 of 4 projects), contributing specialized expertise rather than leading large consortia. They coordinated one SME Instrument project (CMI2T IA), which is typical of small biotechs validating a commercial concept. With 44 unique consortium partners across 8 countries, they have broad exposure to European research networks despite their small size — suggesting they are a sought-after niche contributor rather than a consortium builder.

Despite being a micro-scale SME, Exomnis has collaborated with 44 unique partners across 8 countries, largely through large MSCA training networks and clinical trial consortia. Their network is concentrated in the oncology and radiation therapy research communities of Western Europe.

What sets them apart

Exomnis Biotech occupies a rare niche: using engineered bacteria (Clostridium) as targeted delivery vehicles for immunotherapy drugs in cancer treatment. This biological delivery approach differentiates them from conventional nanoparticle or antibody-drug conjugate companies. For consortium builders, they bring a specialized technology platform that bridges microbiology and oncology — useful for projects needing a drug delivery partner with clinical trial experience.

Highlights from their portfolio

• CMI2T IA
  Their only coordinated project, funded through the SME Instrument — validates their Clostridium-based immunotherapy delivery system as a commercially viable concept.
• IMMUNOSABR
  A phase II clinical trial combining L19-IL2 immunotherapy with SABR for metastatic lung cancer — demonstrates involvement in high-impact translational oncology research.